Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDL Cardiol Therapeutics	$1.17 +0.9%	$1.32	$0.77 ▼ $2.63	$97.94M	1.05	373,659 shs	652,547 shs
EOLS Evolus	$7.43 +2.8%	$8.72	$5.71 ▼ $17.82	$480.57M	1.12	1.11 million shs	838,854 shs
PRTC PureTech Health	$18.53 +0.9%	$18.25	$13.30 ▼ $25.00	$447.05M	1.12	4,377 shs	7,303 shs
REPL Replimune Group	$5.60 +6.7%	$7.95	$2.68 ▼ $17.00	$437.14M	0.67	4.08 million shs	2.70 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDL Cardiol Therapeutics	+1.75%	+4.04%	-4.92%	+8.41%	-38.95%
EOLS Evolus	+1.40%	+11.06%	-21.58%	-24.37%	-50.95%
PRTC PureTech Health	-0.25%	+7.07%	+2.37%	+7.47%	-15.67%
REPL Replimune Group	-0.57%	+3.04%	-57.39%	-40.07%	-50.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDL Cardiol Therapeutics	2.6035 of 5 stars	3.7	2.0	0.0	3.9	0.0	0.6
EOLS Evolus	4.1354 of 5 stars	3.4	1.0	3.5	3.3	3.3	0.6
PRTC PureTech Health	2.7804 of 5 stars	3.8	5.0	0.0	2.6	0.0	0.0
REPL Replimune Group	4.4702 of 5 stars	4.2	2.0	4.5	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	583.76% Upside
EOLS Evolus	2.80	Moderate Buy	$21.25	186.00% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	142.91% Upside
REPL Replimune Group	2.33	Hold	$7.67	36.90% Upside

Current Analyst Ratings Breakdown

Latest CRDL, EOLS, PRTC, and REPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00
8/6/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$27.00 ➝ $20.00
8/6/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$22.00
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
EOLS Evolus	$266.27M	1.80	N/A	N/A	($0.29) per share	-25.62
PRTC PureTech Health	$4.32M	103.60	$2.38 per share	7.78	$17.04 per share	1.09
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-232.26%	-158.19%	N/A
EOLS Evolus	-$50.42M	-$0.98	N/A	N/A	N/A	-22.31%	-759.04%	-24.63%	11/5/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	N/A

Latest CRDL, EOLS, PRTC, and REPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRDL Cardiol Therapeutics	-$0.11	-$0.07	+$0.04	-$0.07	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDL Cardiol Therapeutics	0.01	2.46	3.26
EOLS Evolus	22.00	2.27	1.86
PRTC PureTech Health	N/A	9.33	9.33
REPL Replimune Group	0.21	6.94	6.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDL Cardiol Therapeutics	12.49%
EOLS Evolus	90.69%
PRTC PureTech Health	0.04%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
CRDL Cardiol Therapeutics	5.25%
EOLS Evolus	5.90%
PRTC PureTech Health	5.30%
REPL Replimune Group	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDL Cardiol Therapeutics	20	83.71 million	79.32 million	Not Optionable
EOLS Evolus	170	64.68 million	60.87 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable

CRDL, EOLS, PRTC, and REPL Headlines

Recent News About These Companies

REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

4 hours ago | globenewswire.com

Class Action Filed Against Replimune Group, Inc. (REPL) Seeking Recovery for Investors – Contact The Gross Law Firm

5 hours ago | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 21 at 11:33 AM | globenewswire.com

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

August 21 at 11:10 AM | prnewswire.com

FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial

August 21 at 9:11 AM | statnews.comS

Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

August 20 at 11:09 PM | theglobeandmail.com

Investors in Replimune Group, Inc. (REPL): Protect Your Rights - Contact Levi & Korsinsky Before September 22, 2025

August 20 at 11:09 PM | theglobeandmail.com

Investors Who Lost Money on Replimune Group, Inc. (REPL) Should Contact Levi & Korsinsky About Pending Class Action - REPL

August 20 at 6:09 PM | theglobeandmail.com

REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

August 20 at 3:43 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

August 20 at 1:16 PM | globenewswire.com

Shareholders of Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPL

August 19 at 4:14 PM | globenewswire.com

Class Action Filed Against Replimune Group, Inc. ...

August 19 at 9:31 AM | gurufocus.com

Class Action Filed Against Replimune Group, Inc. (REPL) - September 22, 2025 Deadline to Join - Contact Levi & Korsinsky

August 19 at 8:45 AM | prnewswire.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $7.67 Average Target Price from Analysts

August 19 at 2:23 AM | americanbankingnews.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. ...

August 18 at 5:31 PM | gurufocus.com

Replimune Group, Inc. Class Action: The Gross Law Firm Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 – REPL

August 18 at 4:04 PM | globenewswire.com

Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug – Hagens Berman

August 18 at 12:17 PM | globenewswire.com

Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL)

August 18 at 8:45 AM | prnewswire.com

Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Increases By 165.7%

August 18 at 5:32 AM | marketbeat.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. ...

August 18 at 3:30 AM | gurufocus.com

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

August 18 at 2:53 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, EOLS, PRTC, and REPL Company Descriptions

Cardiol Therapeutics NASDAQ:CRDL

$1.17 +0.01 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 07:34 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Evolus NASDAQ:EOLS

$7.43 +0.20 (+2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$7.38 -0.04 (-0.61%)

As of 05:25 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

PureTech Health NASDAQ:PRTC

$18.52 +0.17 (+0.90%)

As of 04:00 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Replimune Group NASDAQ:REPL

$5.60 +0.35 (+6.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 -0.10 (-1.79%)

As of 07:38 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time